MX357241B - Inhibidores de fosfodiesterasa 10 de pirimidina. - Google Patents
Inhibidores de fosfodiesterasa 10 de pirimidina.Info
- Publication number
- MX357241B MX357241B MX2014002178A MX2014002178A MX357241B MX 357241 B MX357241 B MX 357241B MX 2014002178 A MX2014002178 A MX 2014002178A MX 2014002178 A MX2014002178 A MX 2014002178A MX 357241 B MX357241 B MX 357241B
- Authority
- MX
- Mexico
- Prior art keywords
- pde10 inhibitors
- pyrimidine
- present
- compounds
- pyrimidine pde10
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Abstract
La presente invención se refiere a compuestos de pirimidina que son útiles como agentes terapéuticos para el tratamiento de trastornos del sistema nervioso central asociados con la fosfodiesterasa 10 (PDE10); la presente invención también se refiere al uso de dichos compuestos para tratar trastornos neurológicos y psiquiátricos, tales como la esquizofrenia, la psicosis o la enfermedad de Huntington, y aquellos asociados con la hipofunción del cuerpo estriado o la disfunción de los ganglios basales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527392P | 2011-08-25 | 2011-08-25 | |
| PCT/US2012/051522 WO2013028590A1 (en) | 2011-08-25 | 2012-08-20 | Pyrimidine pde10 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014002178A MX2014002178A (es) | 2014-05-01 |
| MX357241B true MX357241B (es) | 2018-06-29 |
Family
ID=47746797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014002178A MX357241B (es) | 2011-08-25 | 2012-08-20 | Inhibidores de fosfodiesterasa 10 de pirimidina. |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9062059B2 (es) |
| EP (1) | EP2748151B1 (es) |
| JP (1) | JP5648147B2 (es) |
| KR (1) | KR101655635B1 (es) |
| CN (1) | CN103917528B (es) |
| AR (1) | AR087628A1 (es) |
| AU (1) | AU2012299080B2 (es) |
| BR (1) | BR112014004310B8 (es) |
| CA (1) | CA2845578C (es) |
| CL (1) | CL2014000450A1 (es) |
| CO (1) | CO6890101A2 (es) |
| CR (1) | CR20140085A (es) |
| CY (1) | CY1117622T1 (es) |
| DK (1) | DK2748151T3 (es) |
| DO (1) | DOP2014000039A (es) |
| EA (1) | EA023685B1 (es) |
| ES (1) | ES2572527T3 (es) |
| HK (1) | HK1193410A1 (es) |
| HR (1) | HRP20160635T1 (es) |
| HU (1) | HUE028451T2 (es) |
| IL (1) | IL230997A (es) |
| MA (1) | MA35508B1 (es) |
| ME (1) | ME02419B (es) |
| MX (1) | MX357241B (es) |
| MY (1) | MY157301A (es) |
| NI (1) | NI201400014A (es) |
| PE (1) | PE20141535A1 (es) |
| PL (1) | PL2748151T3 (es) |
| RS (1) | RS54788B1 (es) |
| SG (1) | SG2014013536A (es) |
| SI (1) | SI2748151T1 (es) |
| TN (1) | TN2014000070A1 (es) |
| TW (1) | TWI450895B (es) |
| UA (1) | UA109735C2 (es) |
| WO (1) | WO2013028590A1 (es) |
| ZA (1) | ZA201401272B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012318874A1 (en) | 2011-10-06 | 2014-05-15 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine PDE10 inhibitors |
| WO2013052526A1 (en) | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | Triazolyl pde10 inhibitors |
| US9284302B2 (en) | 2012-11-15 | 2016-03-15 | Merck Sharp & Dohme Corp. | Cyclobutyl benzimidazoles as PDE 10 inhibitors |
| TW201422610A (zh) | 2012-11-15 | 2014-06-16 | Merck Sharp & Dohme | 作爲ｐｄｅ１０抑制劑之經二級醇取代之三唑 |
| WO2014078217A1 (en) * | 2012-11-15 | 2014-05-22 | Merck Sharp & Dohme Corp. | Cyclopropyl imidazopyridine pde10 inhibitors |
| EP2922823B1 (en) * | 2012-11-20 | 2018-10-31 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
| EP2922543B1 (en) | 2012-11-20 | 2017-05-24 | Merck Sharp & Dohme Corp. | Substituted pyridone derivatives as pde10 inhibitors |
| WO2014139150A1 (en) * | 2013-03-15 | 2014-09-18 | Merck Sharp & Dohme Corp. | Substituted pyridizinone derivatives as pde10 inhibitors |
| AP2016009374A0 (en) | 2014-03-24 | 2016-08-31 | Novartis Ag | Monobactam organic compounds for the treatment of bacterial infections |
| US10125101B2 (en) | 2016-11-28 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| TWI813203B (zh) * | 2021-03-17 | 2023-08-21 | 美商默沙東有限責任公司 | Pde10化合物之前藥 |
| WO2023184486A1 (en) * | 2022-04-01 | 2023-10-05 | Merck Sharp & Dohme Llc | Process for preparing ( (1s, 2s) -2- (5-methylpyridin-2-yl) cyclopropyl) -methanol |
| CN115403527B (zh) * | 2022-07-20 | 2024-03-29 | 西安近代化学研究所 | 一种还原胺化法合成杀菌剂乙嘧酚的方法 |
| WO2024049721A1 (en) * | 2022-08-31 | 2024-03-07 | Merck Sharp & Dohme Llc | Sustained release delivery of a pde10 inhibitor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2568929A1 (en) | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| EP1810411A2 (en) | 2004-10-12 | 2007-07-25 | Maxlinear, Inc. | A receiver architecture with digitally generated intermediate frequency |
| WO2006072828A2 (en) | 2005-01-07 | 2006-07-13 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as pde10 inhibitors |
| DE602006002271D1 (de) * | 2005-04-05 | 2008-09-25 | Astrazeneca Ab | Pyrimidinderivate zur verwendung als antikrebsmittel |
| GB0506883D0 (en) * | 2005-04-05 | 2005-05-11 | Astrazeneca Ab | Chemical compounds |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| WO2007129183A2 (en) | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
| EP2327704A4 (en) * | 2008-08-29 | 2012-05-09 | Shionogi & Co | RING-CONDENSED AZOL DERIVATIVE WITH PI3K-INHIBITING EFFECT |
| CN102143951A (zh) | 2008-09-04 | 2011-08-03 | 田边三菱制药株式会社 | 三取代嘧啶化合物及其作为pde10抑制剂的用途 |
| JP2012501962A (ja) | 2008-09-10 | 2012-01-26 | 田辺三菱製薬株式会社 | 芳香族含窒素六員環化合物及びその使用 |
| TW201030001A (en) * | 2008-11-14 | 2010-08-16 | Amgen Inc | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
| WO2010077992A1 (en) * | 2008-12-17 | 2010-07-08 | Amgen Inc. | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors |
| WO2011008931A2 (en) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| US8470820B2 (en) * | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
| EP2621926B1 (en) * | 2010-09-30 | 2017-08-30 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde10 inhibitors |
| US8785467B2 (en) * | 2010-09-30 | 2014-07-22 | Merck Sharp & Dohme Corp. | Alkoxy pyrimidine PDE10 inhibitors |
-
2012
- 2012-08-20 CA CA2845578A patent/CA2845578C/en active Active
- 2012-08-20 EA EA201490492A patent/EA023685B1/ru not_active IP Right Cessation
- 2012-08-20 HU HUE12826375A patent/HUE028451T2/en unknown
- 2012-08-20 UA UAA201403008A patent/UA109735C2/ru unknown
- 2012-08-20 PL PL12826375.3T patent/PL2748151T3/pl unknown
- 2012-08-20 KR KR1020147007427A patent/KR101655635B1/ko active IP Right Grant
- 2012-08-20 SG SG2014013536A patent/SG2014013536A/en unknown
- 2012-08-20 TW TW101130166A patent/TWI450895B/zh active
- 2012-08-20 EP EP12826375.3A patent/EP2748151B1/en active Active
- 2012-08-20 RS RS20160357A patent/RS54788B1/sr unknown
- 2012-08-20 DK DK12826375.3T patent/DK2748151T3/en active
- 2012-08-20 MY MYPI2014000504A patent/MY157301A/en unknown
- 2012-08-20 SI SI201230539A patent/SI2748151T1/sl unknown
- 2012-08-20 AU AU2012299080A patent/AU2012299080B2/en active Active
- 2012-08-20 ES ES12826375.3T patent/ES2572527T3/es active Active
- 2012-08-20 US US14/239,603 patent/US9062059B2/en active Active
- 2012-08-20 PE PE2014000255A patent/PE20141535A1/es active IP Right Grant
- 2012-08-20 BR BR112014004310A patent/BR112014004310B8/pt active IP Right Grant
- 2012-08-20 JP JP2014527214A patent/JP5648147B2/ja active Active
- 2012-08-20 CN CN201280052330.4A patent/CN103917528B/zh active Active
- 2012-08-20 MX MX2014002178A patent/MX357241B/es active IP Right Grant
- 2012-08-20 ME MEP-2016-101A patent/ME02419B/me unknown
- 2012-08-20 WO PCT/US2012/051522 patent/WO2013028590A1/en active Application Filing
- 2012-08-22 AR ARP120103086A patent/AR087628A1/es active IP Right Grant
-
2014
- 2014-02-16 IL IL230997A patent/IL230997A/en active IP Right Grant
- 2014-02-18 TN TNP2014000070A patent/TN2014000070A1/en unknown
- 2014-02-19 ZA ZA2014/01272A patent/ZA201401272B/en unknown
- 2014-02-24 CR CR20140085A patent/CR20140085A/es unknown
- 2014-02-24 NI NI201400014A patent/NI201400014A/es unknown
- 2014-02-25 CL CL2014000450A patent/CL2014000450A1/es unknown
- 2014-02-25 DO DO2014000039A patent/DOP2014000039A/es unknown
- 2014-02-27 CO CO14042266A patent/CO6890101A2/es unknown
- 2014-03-13 MA MA6829A patent/MA35508B1/fr unknown
- 2014-07-07 HK HK14106824.3A patent/HK1193410A1/zh unknown
-
2016
- 2016-06-08 HR HRP20160635TT patent/HRP20160635T1/hr unknown
- 2016-06-10 CY CY20161100512T patent/CY1117622T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000070A1 (en) | Pyrimidine pde10 inhibitors | |
| WO2012044561A3 (en) | 2-alkoxy pyrimidine pde10 inhibitors | |
| WO2012044562A3 (en) | Pyrazolopyrimidine pde10 inhibitors | |
| MX2017011935A (es) | Compuestos de triazolil pirimidinona como inhibidores de la enzima fosfodiesterasa 2 (pde2). | |
| WO2012054366A3 (en) | Substituted amino-triazolyl pde10 inhibitors | |
| MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
| AU2012277802A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
| IN2014DN07384A (es) | ||
| MX2015008860A (es) | Inhibidores de 3-(benzoimidazol-2-il)-indazol de la senda de señalizacion de wnt y usos terapeuticos de los mismos. | |
| NZ596078A (en) | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | |
| MX2011011963A (es) | Derivados de 7-aril-1,2,4-triazolo[4,3-a]piridina y uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2). | |
| EA201290244A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10 | |
| NZ596053A (en) | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors | |
| TN2013000325A1 (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases | |
| MY193511A (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
| MX2019014597A (es) | Inhibidores de pirazolopirimidina de pde9. | |
| MX2019005123A (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. | |
| MX2019005115A (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. | |
| MX2015000336A (es) | Inhibidores de la enzima fosfodiesterasa 10. | |
| WO2014150114A8 (en) | Substituted pyridizinone derivatives as pde10 inhibitors | |
| MXPA05012081A (es) | Derivados de pirimidina sustituidos. | |
| PH12014502780A1 (en) | Azetidine and piperidine compounds useful as pde10 inhibitors | |
| ECSP14013268A (es) | Inhibidores de pde10 de pirimidina | |
| CR20230447A (es) | Profármacos de compuestos de pde10 | |
| AR112073A1 (es) | Inhibidores de pirazolopirimidina de pde9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |